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2015). Recent results from a mouse model of malaria supports this
role for complement-dependent invasion inhibition and reported that
antibody-mediated protection from P. yoelii infection malaria after im-Understanding mechanisms of immunity that protect from malaria
is essential for the development of highly effective vaccines. The mero-
zoite form of the parasite, which invades red blood cells, is an important
target of protective immunity (Beeson et al., 2016). Biryukov et al. bring
to our attention the potential ability of complement factors to enhance
P. falciparum merozoite invasion in vitro (Biryukov et al., 2016). They
proposed that i) complement activation at the merozoite surface
enhanced the ability of merozoites to bind and invaded RBCs and ii)
that antibodies tomerozoite surface protein 1 (MSP1) C-terminal region
further enhanced this process. These ﬁndings were primarily demon-
strated with a murine monoclonal antibody (mAb) to MSP1-19, and
some assayswere performedwith samples fromaMSP1-42 phase I vac-
cine trial in malaria-naïve adults. We wish to add further discussion to
the potential relevance of these ﬁndings, and how they differ from pre-
viously published studies to further understand anti-malarial immunity
and pathogenesis.
We previously reported that there is no difference in merozoite in-
vasion efﬁciency in normal, complement active sera compared to heat
inactivated, complement inactive human sera in the absence of immune
antibodies, even at 80% serum concentrations (Boyle et al., 2015). Fur-
ther, we reported that complement active serum signiﬁcantly increases
the inhibitory capacity of naturally acquired and vaccine-induced
human and rabbit antibodies targeting the merozoite (Boyle et al.,
2015). We showed that many antibodies required complement factors
for invasion inhibitory activity, and we demonstrated the importance
of this mechanism for naturally acquired and vaccine induced human
and rabbit antibodies against speciﬁc merozoite proteins including theom.2016.05.015.
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. This is an open access article undermunization with a genetically attenuated parasite vaccine was partly
mediated by antibody interactions with complement (Sack et al.,
2015). Consistentwith theseﬁndings are previous studies in P. chabaudi
models that demonstrate that C1q-deﬁcient animals were signiﬁcantly
more susceptible to secondary challenge with the same parasite stain,
highlighting the central role of C1q and classical complement activation
in acquired immune responses (Taylor et al., 2001).
We disagree with the suggestion of Biryukov et al. that the discrep-
ancy between their and ourﬁndings is due to heighted sensitivity of iso-
lated merozoites to complement activation. As we have previously
shown, isolatedmerozoites are structurally intact, invade at similar efﬁ-
ciencies to standard routine culture, and do not require serum factors to
invade nor show enhanced invasion in serum (Boyle et al., 2010). Since
publication, numerous other studies have used thismethod for isolating
viable merozoites, and increased sensitivity/decreased viability has not
been reported. It is possible that the impact of complement on invasion
is different in standard growth assays as used by Biryukov et al. com-
pared to Boyle et al. (2010), or depending on parasite strains used. How-
ever, we and others have previously included normal sera in growth
assays using a number of different parasite lines; reduced or comparable
growth has been consistently reported, but not enhanced invasion com-
pared to heat inactivated sera ((Campbell et al., 1979; Chulay et al.,
1981; Kennedy et al., 2015) and unpublished data Boyle, Beeson
et al.). It seems more likely that the major difference between the ﬁnd-
ings is the type of antibodies used; naturally acquired and vaccine in-
duce human and rabbit polyclonal antibodies against different
merozoite antigens by Boyle et al. compared to murine mAb or vaccine
induced human antibodies to the C terminal of MSP1 in the case of
Biryukov et al.
While Biryukov et al. propose that mouse monoclonal antibodies to
MSP1-19 augment the enhancement effect of normal sera, the reported
effect was only moderate when considering absolute parasitamias, and
there appears to be large variability in the effect as seen across experi-
mental replicates (data presented in the supplementarymaterials with-
in Biryukov et al., 2016). Data was presented showing a reduced level of
inhibition mediated by sera from MSP1-42 vaccinated malaria-naïve
human subjects in C3/C4 supplemented serum compared to C3/C4the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ference in invasion between complement active and complement
inactivated sera, as would be expected if complement activated sera
signiﬁcantly enhanced invasion and if MSP1-42 C-terminal antibodies
augmented this effect (Biryukov et al., 2016). Further, while Biryukov
et al. support their ﬁndings with in vivo animal models using P. berghei,
complement levels in mice can be very low, and it is unclear how gen-
erally ﬁndings in mice and with mouse antibodies can be applied to
human immunity. Perhaps the phenomena of enhanced invasion in
the presence of mAb MSP1-1-19 can be attributed to a speciﬁc function
of the epitope that this antibody targets and the species of origin of this
antibody, rather than a more general function of antibodies that target
merozoites.
A further consideration is that if antibodies to MSP1 in humans en-
hanced invasion, it might be expected that an MSP1-based vaccine
would increase the risk of parasitemia or malaria incidence. However,
in a phase 2 trial of MSP1-42 (a vaccine designed to generate antibod-
ies), vaccination resulted in increased antibody titres, but had no efﬁca-
cy and did not increase the risk of malaria or parasitemia (Ogutu et al.,
2009). Furthermore, we found that the ability of acquired human anti-
bodies to ﬁx and activate complement on the surface of merozoites,
was associated with a very strong reduction in the risk of malaria and
high density P. falciparum parasitemia (Boyle et al., 2015), the opposite
of the effect that would be seen if complement was important for en-
hancing invasion in vivo. We believe there is strong and growing evi-
dence to support a key role in antibody-dependent complement
activation in inhibition of merozoite invasion, and protection from ma-
laria. We agree with the authors that antibody-complement activity
needs to be measured as part of vaccine candidate assessments in vivo,
to assess antibody function with complement, in contrast to currently
established assays in vitro that use complement-free conditions.
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